Growth Inhibition and Radiosensitization of Glioblastoma and Lung Cancer Cells by Small Interfering RNA Silencing of Tumor Necrosis Factor Receptor–Associated Factor 2
Open Access
- 14 September 2008
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (18) , 7570-7578
Abstract
Radiotherapy combined with chemotherapy is the treatment of choice for glioblastoma and locally advanced lung cancer, but radioresistance of these two types of cancer remains a significant therapeutic hindrance. To identify molecular target(s) for radiosensitization, we screened a small interfering RNA (siRNA) library targeting all protein kinases and E3 ubiquitin ligases in the human genome and identified tumor necrosis factor receptor–associated factor 2 (TRAF2). Silencing of TRAF2 using siRNA caused a significant growth suppression of glioblastoma U251 cells and moderately sensitized these radioresistant cells to radiation. Overexpression of a really interesting new gene (RING)–deleted dominant-negative TRAF2 mutant also conferred radiosensitivity, whereas overexpression of wild-type (WT) TRAF2 significantly protected cells from radiation-induced killing. Likewise, siRNA silencing of TRAF2 in radioresistant lung cancer H1299 cells caused growth suppression and radiosensitization, whereas overexpression of WT TRAF2 enhanced radioresistance in a RING ligase-dependent manner. Moreover, siRNA silencing of TRAF2 in UM-SCC-1 head and neck cancer cells also conferred radiosensitization. Further support for the role of TRAF2 in cancer comes from the observations that TRAF2 is overexpressed in both lung adenocarcinoma tissues and multiple lung cancer cell lines. Importantly, TRAF2 expression was very low in normal bronchial epithelial NL20 cells, and TRAF2 silencing had a minimal effect on NL20 growth and radiation sensitivity. Mechanistically, TRAF2 silencing blocks the activation of the nuclear factor-κB signaling pathway and down-regulates several G2-M cell cycle control proteins, resulting in enhanced G2-M arrest, growth suppression, and radiosensitization. Our studies suggest that TRAF2 is an attractive drug target for anticancer therapy and radiosensitization. [Cancer Res 2008;68(18):7570–8]Keywords
This publication has 50 references indexed in Scilit:
- G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancerBritish Journal of Cancer, 2008
- Ribosomal protein S27L is a direct p53 target that regulates apoptosisOncogene, 2006
- E3 Ubiquitin Ligases as Cancer Targets and BiomarkersNeoplasia, 2006
- Nuclear factor-κB in cancer development and progressionNature, 2006
- XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancerOncogene, 2004
- Development of a High Throughput Time-Resolved Fluorescence Resonance Energy Transfer Assay for TRAF6 Ubiquitin PolymerizationASSAY and Drug Development Technologies, 2003
- Gene-expression profiles predict survival of patients with lung adenocarcinomaNature Medicine, 2002
- Tissue microarrays (TMAs) for high-throughput molecular pathology researchInternational Journal of Cancer, 2001
- Delineation of prognostic biomarkers in prostate cancerNature, 2001
- A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening AssaysSLAS Discovery, 1999